leisure time -WSS

leisure time

author：comprehensive 2025-09-02 08:19:44 - browse：646

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Hospital price transparency does save money, advocate argues

hotspot

WSS

UnitedHealth’s board chair also owns a personal investment firm

STAT Summit: Michael J. Fox on progress in Parkinson's research

Allen Institute goes after foundational questions, CEO Costa says

A preacher's new calling: Diversifying neuroscience research

Profiling embryos to choose those with higher IQs is almost a reality

Boston Scientific acquires urology company Axonics for $3.7 billion

entertainment

leisure time

focus

Psychedelics group wrestles with new pharma identity

Beam Therapeutics to lay off 20% of its staff, re

Wildfire smoke exposes gaps in outdoor worker protections

Medicare Advantage coverage denials need scrutiny, senators say

As demand for Covid shots wanes, Moderna seeks its next success

How climate

Duchenne breakthrough therapy leaves behind pioneering families

The EU Joint Clinical Assessment needs to live up to its promise

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

UnitedHealth’s board chair also owns a personal investment firm

Wikipedia

JPM pitch from hospitals? Revenue streams outside of patient care

Beam Therapeutics to lay off 20% of its staff, re

STAT Summit: GSK CEO on pharma giant's new direction

Gene therapy denied for Afghan refugee whose father aided U.S.

STAT Summit: Biotech founders on deal

FDA warns J&J's Abiomed: We will regulate your software

Wikipedia

Wikipedia

hotspot

hotspot